2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Imaging, Molecular Testing, Serologic Tests, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Biological Processes, Pathogenesis, Genomics, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Measurable Residual Disease, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Study Population, Human, Adult
PAPER

2194 κ light chain isotype predicts high-quality cardiac response in AL amyloidosis patients achieving hematologic complete response

Xinyi Xiong, MD, Kaini Shen, MD2, Marco Basset, MD3, Ai Guan, MD4, Claudia Bellofiore, MD5, Chengyang Xu6, Mario Nuvolone Jr, MD, PhD7, Yi Xu Jr, PhD8, Jian Li, MD9, Giovanni Palladini, MD,PhD10, Poalo Milani11
1 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
2 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
3 Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, Department of Molecular Medicine, University of Pavia, Pavia, Italy
4 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
5 Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, Department of Molecular Medicine, University of Pavia, Pavia, Italy
6 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
7 Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, Department of Molecular Medicine, University of Pavia, Pavia, Italy
8 Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
9 Center for Rare Diseases, State Key Laboratory of Complex, Severe, and Rare Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
10 Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, Department of Molecular Medicine, University of Pavia, Pavia, Italy
11 Amyloidosis Research and Treatment Center, Foundation IRCCS Policlinico San Matteo, Pavia, Italy, Department of Molecular Medicine, University of Pavia, Pavia, Italy

Background: In immunoglobulin light-chain (AL) amyloidosis, hematologic complete response (CR) represents the principal therapeutic goal; however, deep hematologic responses do not uniformly translate into concordant cardiac responses, which remain the major determinant of survival. The factors governing this discordance remain incompletely understood. To minimize the confounding effect of hematologic response depth, we restricted our analysis to patients achieving hematologic CR and investigated baseline and treatment-related predictors of cardiac response.

Methods: We retrospectively analyzed 404 patients with AL amyloidosis from two centers (2004–2024) who achieved hematologic CR after first-line therapy, had evaluable baseline cardiac involvement (NT-proBNP >650 ng/L or BNP >150 ng/L), and underwent cardiac response assessment through 24 months. Baseline characteristics were compared according to light chain isotype. Serum free light chains (FLC) were measured with the Freelite assay. Endpoints were ≥cardiac partial response (≥carPR) at 12 months and ≥cardiac very good partial response (≥carVGPR) and cardiac complete response (carCR) at 24 months. Predictors identified by univariate logistic regression were entered into multivariable models for the entire cohort and separately for the daratumumab-treated subgroup (N=127).

Median age was 60 years (range 34–85) with 33% ≥65; 56% were male and 327 (81%) had λ isotype. Median involved organ number was 2 (>2 in 21%); renal involvement 58%, hepatic 16%. Mayo 2004 stage II/IIIa/IIIb was 56%/31%/13%, NYHA class 3/4 32%, median NT-proBNP 3,289 ng/L (>8500 in 18%), cTnI 0.08 μg/L (>0.1 in 42%), IVS 14.0 mm (>14 mm in 43%), and EF 59% (<50% in 18%). First-line therapy was bortezomib-based in 53%, daratumumab-based in 31%, and alkylator-based in 11%. Hematologic CR was attained within 3, 6, and 12 months in 38%, 83%, and 94%, respectively; 6% lost CR within 24 months.

Within this hematologic-CR cohort, κ patients carried a greater clonal burden and cleared more slowly: higher dFLC (319 vs 194 mg/L, P=0.008; ≥180 mg/L in 70% vs 53%, P=0.008), slightly higher bone marrow plasma cells (8% vs 6%, P=0.038), more hepatic involvement (32% vs 12%, p<0.001), and lower rates of hematologic CR within 3 months (25% vs 41%, P=0.009), 6 months (68% vs 87%, p<0.001), and 12 months (84% vs 96%, P=0.001). Baseline cardiac parameters were comparable, with a trend toward less frequent IVS >14 mm in κ (32% vs 45%, P=0.056).

Overall, ≥carPR and ≥carVGPR rates were 71% and 43% at 12 months, and 78% and 57% at 24 months, respectively. In multivariable analysis of the entire cohort, 12-month ≥carPR was independently predicted by hematologic CR achievement within 3 months (OR 1.88, 95% CI 1.12–3.19; P=0.017) and IVS >14 mm (OR 1.77, 95% CI 1.10–2.89; P=0.020). Independent predictors of 24-month ≥carVGPR were κ isotype (OR 2.71, 95% CI 1.53–4.98; p<0.001), age <65 years (OR 1.62, 95% CI 1.04–2.52; P=0.032), and ≤2 involved organs (OR 2.01, 95% CI 1.20–3.42; P=0.009), while first-line daratumumab treatment showed a favorable trend (OR 1.51, 95% CI 0.95–2.41; P=0.080).

Among daratumumab-treated patients, κ isotype remained an independent predictor of 24-month ≥carVGPR (OR 4.67, 95% CI 1.44–21.1; P=0.020), whereas age <65 years predicted carCR (OR 4.74, 95% CI 1.49–21.1; P=0.017). Renal involvement was associated with lower rates of 24-month ≥carVGPR and carCR in univariate analyses (P=0.042 and P=0.047, respectively), but these associations were attenuated after adjustment (OR 0.52, 95% CI 0.23–1.16, P=0.11; OR 0.42, 95% CI 0.15–1.07, P=0.074, respectively).

Conclusions: Among patients with AL amyloidosis achieving hematologic CR, κ isotype independently predicts high-quality 24-month cardiac response. Younger age and limited organ involvement also favor deeper cardiac recovery, whereas early hematologic CR within 3 months predicts earlier cardiac improvement without translating into superior long-term cardiac depth. Slower hematologic clearance in κ should be read cautiously, as Freelite is known to overestimate FLC-κ. Once hematologic CR is achieved, cardiac recovery appears to be influenced more by light chain isotype and host factors than by the kinetics of clonal clearance, supporting isotype-aware expectations in cardiac response assessment and clinical trial design.

Xinyi Xiong, MD: No relevant conflicts of interest to declare.